News

BioSpace1h
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...
Barchart on MSN18h
The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.
Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...
BMJ Case Reports2d
Hereditary angioedema in a paediatric patient presenting with abdominal pain and duodenal dilation
Hereditary angioedema (HAE) is a genetic disorder that causes sudden episodes of swelling, often accompanied by abdominal pain. Affecting roughly 1 in 50 000 people, HAE typically appears in childhood ...
BioSpace1d
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)
Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...
Newseria BIZNES6d
Hereditary Angioedema (HAE): Competitive Intelligence Insight into Next-Gen Treatment Strategies | DataM Intelligence
Hereditary Angioedema (HAE) is a rare genetic disorder marked by sudden, severe swelling episodes in the skin, gut, or airway ...
Leading Factor Driving The Angioedema Treatment Market In 2025: Rise In Rare Disease Diagnoses Fueling The Growth
Angioedema Treatment Global Market Report 2025. The Business Research Company's Angioedema Treatment Global Market Report 2025 – Market Size, Trends, And ...